Pulmonology

Risk Factors and Planning for Advanced Care

At a Glance

With rheumatoid arthritis-associated interstitial lung disease, older age at diagnosis, male sex, smoking, a scarring pattern called UIP, and emphysema are linked to a higher risk of progression. Regular monitoring and early discussions about transplant or supportive care help guide planning.

As you navigate life with RA-ILD, understanding the factors that influence your long-term outlook can help you and your care team make proactive decisions. While every person’s journey is unique, certain risk factors and secondary conditions can change the “pace” of the disease and may require more intensive management ^[1]^[2].

Factors That Influence Your Outlook

Researchers have identified several key factors that are associated with a higher risk of disease progression or complications. Knowing these helps your doctor determine how closely you need to be monitored ^[1]:

Demographics: Statistics show that older age at diagnosis and male sex are both associated with a higher risk of more aggressive disease ^[1]^[3].
Smoking History: Smoking is a major driver of poor outcomes ^[1]. It is linked to both a faster decline in lung function and a higher risk of life-threatening “acute exacerbations” ^[4].
The UIP Pattern: As mentioned in previous pages, having a UIP (Usual Interstitial Pneumonia) pattern on your scans is often a sign of more persistent scarring compared to other patterns ^[1]^[5].
Co-existing Emphysema: If your scans show both ILD (scarring) and emphysema (damage to the air sacs often caused by smoking), the risk of complications is significantly higher ^[1]. One meta-analysis found that patients with both conditions had more than double the mortality risk compared to those with ILD alone ^[1].

A Serious Complication: Pulmonary Hypertension

In advanced RA-ILD, the scarring can make it harder for blood to flow through the lungs. This causes the blood pressure in the lung arteries to rise, a condition called Pulmonary Hypertension (PH) ^[2].

This is a serious complication because it puts extra strain on the right side of the heart. For example, one study found that an estimated Systolic Pulmonary Artery Pressure (SPAP) of 37 mmHg or higher on an echocardiogram was a strong signal of a higher risk for poor outcomes ^[6]. However, this number is an estimate, not a strict diagnostic rule, and echocardiograms can be inaccurate. If indicated, PH is formally evaluated using right-heart catheterization. Symptoms to watch for include:

New or worsening swelling in the ankles or legs (edema).
Feeling lightheaded or fainting during activity (syncope).
A feeling of pressure or pain in the chest.

Planning for Advanced Care

For most patients, RA-ILD is a chronic condition managed with medications for many years. However, for some, the disease may continue to progress despite the best available treatments. This is where “advanced care planning” becomes an empowering tool rather than a source of fear ^[7].

Lung Transplant Evaluation

A lung transplant is a major surgery that can be life-saving for patients with advanced, progressive disease ^[7]. Because the evaluation process is very thorough and can take months, it is often best to start the conversation early ^[7].

Your doctor may suggest a referral to a transplant center if you experience indicators such as:

Rapid Decline: A drop in your FVC (lung volume) of 10% or more within a single year ^[8]^[9].
Severe Impairment: A DLCO (oxygen transfer) score that falls below 40% of what is predicted for your age ^[10]^[11].
Escalating Oxygen Needs: Needing significantly more supplemental oxygen just to perform basic daily tasks ^[9].
Hospitalizations: Any hospital stay for an acute lung “flare” or exacerbation ^[9]^[12].

These are common considerations for early referral, not fixed rules. Being referred for an evaluation does not mean you need surgery tomorrow; it means the transplant team wants to get to know you, optimize your health, and ensure you are ready if the time comes ^[7].

Palliative and Supportive Care

Advanced care planning also includes palliative care, which is specialized medical care focused on providing relief from symptoms and stress at any stage of disease. Discussing goals of care, advance directives, and symptom-focused support (like managing severe breathlessness) allows you to be an active participant in your care at every stage of the journey.

Common questions in this guide

Which factors can make rheumatoid arthritis-associated interstitial lung disease worse?

Older age when RA-ILD is diagnosed, male sex, a history of smoking, a UIP scarring pattern on scans, and co-existing emphysema are linked with a higher risk of progression or complications. These factors do not determine one person’s outcome, but they can help the care team decide how closely to monitor the lungs.

What symptoms could suggest pulmonary hypertension in RA-ILD?

Pulmonary hypertension means that pressure in the blood vessels of the lungs is elevated, which can strain the right side of the heart. New or worsening ankle or leg swelling, lightheadedness or fainting with activity, and chest pressure or pain should be discussed promptly with a clinician.

How is pulmonary hypertension checked or confirmed?

An echocardiogram can estimate pressure in the lung arteries, but the estimate is not a definitive diagnosis. When pulmonary hypertension is suspected, right-heart catheterization may be used to measure the pressure directly and confirm it.

When should I ask about a lung transplant evaluation for RA-ILD?

Early referral may be considered if lung volume called FVC falls by 10% or more in a year, oxygen-transfer capacity called DLCO falls below 40% of predicted, oxygen needs rise, or you are hospitalized for an acute flare. These are common referral considerations rather than strict rules, and referral does not mean a transplant is immediately required.

Does being referred to a transplant center mean I will need a transplant soon?

No. A referral gives the transplant team time to evaluate your health, help optimize your condition, and determine whether transplantation could be appropriate if the disease progresses. The evaluation can take months, so discussing it early may be useful.

Can palliative care help if I have advanced RA-ILD?

Yes. Palliative care can be added at any stage to ease breathlessness and other symptoms, reduce stress, and help you discuss treatment goals and advance directives. It is supportive care and is not limited to the final stage of life.

How does emphysema affect the outlook for someone with RA-ILD?

When emphysema and interstitial lung disease occur together, the risk of complications and death can be higher than with interstitial lung disease alone. A smoking history can worsen lung function and raise the risk of acute exacerbations, so complete smoking abstinence is especially important if transplant evaluation is being considered.

Get notified when new evidence is published on rheumatoid arthritis-associated interstitial lung disease.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Key takeaways

Older age at diagnosis, male sex, smoking, a UIP pattern, and co-existing emphysema are associated with a higher risk of RA-ILD progression or complications.
Pulmonary hypertension can develop when lung scarring raises pressure in the lung arteries and strains the right side of the heart.
New leg swelling, lightheadedness or fainting during activity, and chest pressure or pain may signal a need to evaluate for pulmonary hypertension.
Lung transplant referral may be considered after an FVC decline of 10% or more in one year, DLCO below 40% of predicted, rising oxygen needs, or hospitalization for an acute exacerbation, but these are not fixed rules.
Palliative and supportive care can relieve symptoms and support advance care planning at any stage, while early transplant discussions allow time for evaluation.

References (12)

1
Factors associated with mortality in rheumatoid arthritis-associated interstitial lung disease: a systematic review and meta-analysis.
Qiu M, Jiang J, Nian X, et al.
Respiratory research 2021; (22(1)):264 doi:10.1186/s12931-021-01856-z.
PMID: 34635095
2
Rheumatoid arthritis-associated interstitial lung disease: Pathogenesis, risk stratification, and management.
Gao R, Liu S, Song L
Respiratory medicine 2026; (261()):109066 doi:10.1016/j.rmed.2026.109066.
PMID: 42521038
3
A Systematic Review of the Key Predictors of Progression and Mortality of Rheumatoid Arthritis-Associated Interstitial Lung Disease.
Groseanu L, Niță C
Diagnostics (Basel, Switzerland) 2024; (14(17)) doi:10.3390/diagnostics14171890.
PMID: 39272673
4
Incidence, risk factors, and prognosis of acute exacerbation of rheumatoid arthritis-associated interstitial lung disease: a systematic review and meta-analysis.
Xie M, Zhu C, Ye Y
BMC pulmonary medicine 2023; (23(1)):255 doi:10.1186/s12890-023-02532-2.
PMID: 37434169
5
Impact of the pattern of interstitial lung disease on mortality in rheumatoid arthritis: A systematic literature review and meta-analysis.
Singh N, Varghese J, England BR, et al.
Seminars in arthritis and rheumatism 2019; (49(3)):358-365 doi:10.1016/j.semarthrit.2019.04.005.
PMID: 31153706
6
Prevalence and clinical significance of anti-neutrophil cytoplasmic antibodies in rheumatoid arthritis-associated interstitial lung disease.
Huang Z, Wu T, Lu R, et al.
BMC pulmonary medicine 2025; (25(1)):177 doi:10.1186/s12890-025-03644-7.
PMID: 40229742
7
Management issues in rheumatoid arthritis-associated interstitial lung disease.
England BR, Hershberger D
Current opinion in rheumatology 2020; (32(3)):255-263 doi:10.1097/BOR.0000000000000703.
PMID: 32141954
8
Forced vital capacity trajectories and risk of lung transplant and ILD-related mortality among patients with rheumatoid arthritis-associated interstitial lung disease.
Venkat RK, Hayashi K, Juge PA, et al.
Clinical rheumatology 2024; (43(8)):2453-2466 doi:10.1007/s10067-024-07028-w.
PMID: 38898318
9
Heterogeneity of Rheumatoid Arthritis-Associated Interstitial Lung Disease by Longitudinal Forced Vital Capacity Trajectory and Associations With Disease Outcomes.
England BR, Yang Y, Roul P, et al.
Arthritis care & research 2026; (78(2)):249-258 doi:10.1002/acr.25620.
PMID: 40771150
10
Risk factors for progression and prognosis of rheumatoid arthritis-associated interstitial lung disease: single center study with a large sample of Chinese population.
Fu Q, Wang L, Li L, et al.
Clinical rheumatology 2019; (38(4)):1109-1116 doi:10.1007/s10067-018-4382-x.
PMID: 30535993
11
Are risk predicting models useful for estimating survival of patients with rheumatoid arthritis-associated interstitial lung disease?
Nurmi HM, Purokivi MK, Kärkkäinen MS, et al.
BMC pulmonary medicine 2017; (17(1)):16 doi:10.1186/s12890-016-0358-2.
PMID: 28086844
12
Acute exacerbation of rheumatoid arthritis-associated interstitial lung disease: mortality and its prediction model.
Hozumi H, Kono M, Hasegawa H, et al.
Respiratory research 2022; (23(1)):57 doi:10.1186/s12931-022-01978-y.
PMID: 35277175

This page is for informational purposes only and does not constitute medical advice. Your pulmonologist and care team can help interpret your RA-ILD risk factors and discuss pulmonary hypertension, transplant evaluation, and care goals.

Guide Contents